Disclosures for "Improvement of Troublesome Dyskinesia in People with Parkinson’s Disease Treated with Foslevodopa/Foscarbidopa"
-
Dr. Blaabjerg has nothing to disclose.
-
The institution of Dr. Liang has received research support from Bial R&D Investments S.A.. The institution of Dr. Liang has received research support from Parkinson's Foundation. The institution of Dr. Liang has received research support from AbbVie. The institution of Dr. Liang has received research support from Neuroderm. Dr. Liang has received publishing royalties from a publication relating to health care.
-
The institution of Dr. Peckham has received research support from abbvie. The institution of Dr. Peckham has received research support from lilly. The institution of Dr. Peckham has received research support from Amlyx. The institution of Dr. Peckham has received research support from Cerevel. The institution of Dr. Peckham has received research support from Sage. The institution of Dr. Peckham has received research support from Annovis. The institution of Dr. Peckham has received research support from AriBio. The institution of Dr. Peckham has received research support from Ferrer. The institution of Dr. Peckham has received research support from Biogen. The institution of Dr. Peckham has received research support from UCB. The institution of Dr. Peckham has received research support from Roche. The institution of Dr. Peckham has received research support from Cerevance. The institution of Dr. Peckham has received research support from Aptinyx.
-
Author has nothing to disclose
-
Lars Bergmann has received personal compensation for serving as an employee of Abbvie. Lars Bergmann has stock in Abbvie.
-
Resmi Gupta has nothing to disclose.
-
Ms. Harmer has received personal compensation for serving as an employee of AbbVie. Ms. Harmer has stock in AbbVie.
-
Megha Shah has received personal compensation for serving as an employee of AbbVie. Megha Shah has stock in AbbVIe .
-
The institution of Filip Bergquist has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Filip Bergquist has received personal compensation in the range of $10,000-$49,999 for serving as an officer or member of the Board of Directors for Arvid Carlsson Research AB. The institution of Filip Bergquist has received research support from Swedish Government. The institution of Filip Bergquist has received research support from Parkinsonfonden. The institution of Filip Bergquist has received research support from Neuro Sweden. The institution of Filip Bergquist has received research support from Swedish Research Council. Filip Bergquist has received publishing royalties from a publication relating to health care. Filip Bergquist has received publishing royalties from a publication relating to health care. Filip Bergquist has a non-compensated relationship as a Advisor with Sense4Care that is relevant to AAN interests or activities.